Profile data is unavailable for this security.
About the company
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-51.69m
- Incorporated2018
- Employees12.00
- LocationCytodyn Inc1111 Main St Ste 660VANCOUVER 98660-2970United StatesUSA
- Phone+1 (360) 980-8524
- Fax+1 (302) 655-5049
- Websitehttps://www.cytodyn.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc | 0.00 | -1.35m | 223.75m | -- | -- | 0.992 | -- | -- | -0.0938 | 13.87 | 0.00 | 15.25 | 0.00 | -- | -- | -- | -1.02 | -23.52 | -1.12 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 224.23m | 46.00 | -- | 1.90 | -- | 13.82 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 224.95m | 51.00 | -- | 1.22 | -- | 13.93 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 225.18m | 10.00 | -- | 1.99 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 226.18m | 274.00 | -- | 1.09 | -- | 3.18 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Codexis Inc | 74.23m | -65.13m | 227.20m | 174.00 | -- | 2.87 | -- | 3.06 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Design Therapeutics Inc | 0.00 | -58.67m | 227.68m | 57.00 | -- | 0.8446 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 228.46m | 167.00 | -- | -- | -- | 1.22 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.40 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 82.75 | 69.13 | -22.98 | -82.25 | 1.31 | -5.00 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 230.60m | 249.00 | -- | -- | -- | 0.7639 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Boundless Bio Inc | -100.00bn | -100.00bn | 234.12m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.69m | 234.93m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| Invivyd Inc | 0.00 | -206.82m | 239.82m | 94.00 | -- | 1.34 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 242.75m | 133.00 | -- | 1.31 | -- | 228.15 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Chromadex Corp | 83.17m | -3.53m | 245.50m | 106.00 | -- | 8.44 | -- | 2.95 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Data as of May 24 2024. Currency figures normalised to Cytodyn Inc's reporting currency: US Dollar USD
0.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Diversified Trust Co.as of 31 Mar 2024 | 45.79k | 0.01% |
| Virtue Capital Management LLCas of 31 Mar 2024 | 45.00k | 0.01% |
| Next Capital Management LLCas of 31 Mar 2024 | 32.50k | 0.00% |
| Moloney Securities Asset Management LLCas of 31 Mar 2024 | 28.03k | 0.00% |
| Williams Jones Wealth Management LLCas of 31 Mar 2024 | 19.00k | 0.00% |
| S.A. Mason LLCas of 31 Mar 2024 | 19.00k | 0.00% |
| Horizon Financial Services LLCas of 31 Mar 2024 | 18.20k | 0.00% |
| FineMark National Bank & Trust (Invt Mgmt)as of 31 Mar 2024 | 15.00k | 0.00% |
| Willis Investment Counsel, Inc.as of 31 Mar 2024 | 13.04k | 0.00% |
| Ancora Family Wealth Advisors LLCas of 31 Mar 2024 | 9.49k | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
